MicroRNAs (miRNAs) have emerged as novel cancer genes. In particular, the miR-17-92 cluster, containing six individual miRNAs, is highly expressed in haematopoietic cancers and promotes lymphomagenesis in vivo. Clinical use of these findings hinges on isolating the oncogenic activity within the 17-92 cluster and defining its relevant target genes. Here we show that miR-19 is sufficient to promote leukaemogenesis in Notch1-induced T-cell acute lymphoblastic leukaemia (T-ALL) in vivo. In concord with the pathogenic importance of this interaction in T-ALL, we report a novel translocation that targets the 17-92 cluster and coincides with a second rearrangement that activates Notch1. To identify the miR-19 targets responsible for its oncogenic action, we conducted a large-scale short hairpin RNA screen for genes whose knockdown can phenocopy miR-19. Strikingly, the results of this screen were enriched for miR-19 target genes, and include Bim (Bcl2L11), AMP-activated kinase (Prkaa1) and the phosphatases Pten and PP2A (Ppp2r5e). Hence, an unbiased, functional genomics approach reveals a coordinate clampdown on several regulators of phosphatidylinositol-3-OH kinase-related survival signals by the leukaemogenic miR-19. miRNAs are ubiquitous regulators of biological processes involved in normal development, differentiation, and diseases including cancer. They act by regulating gene expression at the transcriptional and translational levels 1 . Several methods have been devised to identify genes that are regulated by miRNAs; programs such as Targetscan can identify potential miRNA targets on the basis of conserved sequence complementarity [2][3][4] . Experimental tools can define the actual effects of miRNAs on gene expression, for example expression profiles and comparative proteomics (stable isotope labelling with amino acids in cell culture; SILAC) 5, 6 , or measurements of incorporation into the miRNA machinery (highthroughput sequencing of RNAs isolated by crosslinking immunoprecipitation; HITS-CLIP) 7 . These approaches are capable of predicting or identifying a large number of miRNA target genes; however, most probably only a limited number of miRNA targets are directly responsible for a specific phenotype 8 . An unbiased way of identifying these functionally relevant miRNA targets is needed for an understanding of the biological basis of miRNA activity.
miRNAs are ubiquitous regulators of biological processes involved in normal development, differentiation, and diseases including cancer. They act by regulating gene expression at the transcriptional and translational levels 1 . Several methods have been devised to identify genes that are regulated by miRNAs; programs such as Targetscan can identify potential miRNA targets on the basis of conserved sequence complementarity [2] [3] [4] . Experimental tools can define the actual effects of miRNAs on gene expression, for example expression profiles and comparative proteomics (stable isotope labelling with amino acids in cell culture; SILAC) 5, 6 , or measurements of incorporation into the miRNA machinery (highthroughput sequencing of RNAs isolated by crosslinking immunoprecipitation; HITS-CLIP) 7 . These approaches are capable of predicting or identifying a large number of miRNA target genes; however, most probably only a limited number of miRNA targets are directly responsible for a specific phenotype 8 . An unbiased way of identifying these functionally relevant miRNA targets is needed for an understanding of the biological basis of miRNA activity.
The oncogenic 17-92 cluster of miRNAs is of eminent importance in human haematopoietic cancers [9] [10] [11] . Overexpression of the 17-92 cluster produces a benign lymphoproliferation and can cooperate with c-Myc in causing Burkitt's lymphoma in mice 9, 10 . The cluster has two paralogues and together they encode 15 miRNAs with overlapping functions in development 12 . miR-19 is clearly important in cooperating with c-Myc or enhancing the transplantation of Burkitt's lymphoma cells 13, 14 ; however, it has not been established which particular miRNA(s) deliver the oncogenic activity of these clusters in leukaemia. Moreover, although comprehensive lists of potential targets of the 17-92 cluster are available, and some individual candidates have been confirmed experimentally 12, 15, 16 , the mechanism responsible for its oncogenicity remains unknown.
ReSuLTS

Distinct role of miR-19 in lymphocyte survival and transformation
To identify the oncogenic activity within the 17-92 cluster and its paralogues we used an in vitro assay of haematopoietic transformation 17 . We tested all miRNAs representing families of seed sequences, specifically miR-17, miR-18a, miR-19b-1 (miR-19), miR-20a, miR-106a, miR-106b and miR-25 ( Fig. 1a ) 12 . The assay is based on the interleukin-3 (IL-3) dependence of FL5-12 lymphocytes, which undergo apoptosis when removed from IL-3. We partly transduced FL5-12 cells with the individual miRNAs and green fluorescent protein (GFP) or empty vector (MIG), and monitored these mixed populations by fluorescence-activated cell sorting (FACS) for changes in their relative proportions (Fig. 1b) . FL5-12 cells expressing miR-19 were rapidly enriched over parental cells after depletion of IL-3, and none of the other miRNAs had a similar protective effect ( Fig. 1c) (miR-19, P < 0.002; all other miRNAs and vector, P > 0.05; t-test). Next, we determined whether the effect was due to a decrease in cell death or to an effect on proliferation. miR-19 showed direct protection from cell death in FL5-12 cells after withdrawal of IL-3 (FL5-12/vector, viability 49 ± 1% (mean ± s.d.)); FL5-12/miR-19, viability 82 ± 1.5%; P < 6 × 10 −6 ) ( Fig. 1d) . By contrast, miR-19 had little effect on cell proliferation, such that 24 h after release the fraction of synchronized FL5-12 cells in S phase was indistinguishable between vector-transduced and miR-19-transduced cells (FL5-12/vector, 24 ± 3%; FL5-12/miR-19, 24.5 ± 0.5%; P = 0.8) (not shown). Hence, miR-19 has a distinct ability within the 17-92 cluster to protect lymphocytes from apoptosis after depletion of growth factors.
The 17-92 cluster of miRNAs has been studied extensively in a murine model of Burkitt' s lymphoma 10, 13, 14 . To confirm the dominant role of miR-19 in that model, we transduced lymphoma cells with a pool of miRNAs that included all 17-92 members. We then transplanted these cells into non-irradiated recipient mice and sequenced the integrated miRNA vectors from the resulting tumours (Fig. 2a) . As expected, we found a marked enrichment of miRNA/GFP-expressing cells. Strikingly, all sequences (20 out of 20 clones) derived from the tumour identified the miR-19 construct (Fig. 2b) . Consistent with its ability to block apoptosis in vitro was our observation that miR-19 was also sufficient to prevent p53 loss of heterozygosity (LOH) in tumours derived from p53 which inevitably undergo p53 LOH in vector controls ( Supplementary  Information, Fig. S1 ). Clearly, miR-19 is sufficient to affect lymphocyte survival and transformation in vitro and in vivo.
miR-19 is a novel oncogene in acute T-ALL
We assessed the expression of miR-19 in a panel of human lymphatic malignancies to determine its relevance in these cancers. In comparison with lymphocytes from tonsils, we found a 5-17-fold increased expression of miR-19 in T-ALL (n = 3) ( Fig. 3a ; Supplementary Information, Table S1 ). Moreover, miR-19 showed the highest expression of all miRNAs encoded in the 17-92 cluster in this disease ( Supplementary Information, Fig. S2a ). miR-19 was also highly expressed in B-cell acute lymphoblastic leukaemia (B-ALL) and aggressive lymphomas including diffuse large B-cell lymphoma and Burkitt's disease. In concord with previous profiling studies 18, 19 , we found lower levels in indolent follicular lymphomas. The retroviral expression of miR-19 in FL5-12 cells produced levels that were comparable to those seen in some tumour and leukaemia specimens (red bar in Fig. 3a) .
The 17-92 cluster is the target of a novel translocation in T-ALL. Karyotype analysis of an adult patient with T-ALL revealed the coexistence of two clonal translocations involving both TCRA/D loci in chromosome band 14q11. The first rearrangement, t(9;14)(q34;q11), affects the NOTCH1 gene locus in chromosome band 9q34, and 5´ rapid amplification of cDNA ends confirmed the expression of a constitutively active form of NOTCH1 (exons 29-34) ( Supplementary Information, Fig. S2b-d ) 20, 21 . The second rearrangement, t(13;14)(q32;q11), also involving the TCRA/D locus, was novel and pinpointed a new T-ALL oncogene at 13q32. A fluorescence in situ hybridization analysis using genomic clones RP11-980D6 and RP11-97P7 revealed a split signal between chromosome 13 and the derivative chromosome 14, and mapped the breakpoint close to the 17-92 cluster t(13;14)(q32;q11) ( Fig. 3b, c; Supplementary Information, Fig. S2e ). Thus, dual translocations that simultaneously affect the 17-92 cluster and Notch1 indicate the oncogenic importance of this interaction in T-ALL.
Indeed, most cases of T-ALL show mutations or translocations that result in increased expression or constitutive Notch1 activity [20] [21] [22] . To determine whether miR-19 could enhance Notch1-induced T-ALL in vivo, we co-transduced HPCs from fetal livers with Notch-ICN (intracellular cleaved Notch1) and miR-19 or empty vector 23 . We then transplanted the HPCs into irradiated recipients and monitored them for the onset of frank leukaemia (Fig. 3d) . Mice receiving HPCs expressing both Notch-ICN and miR-19 succumbed to ALL in about 2 months. At the same time, 80% of the mice receiving Notch-ICN remained healthy (P = 0.0003) (Fig. 3e) . Pathology confirmed the diagnosis of T-ALL with der (14) der (14) der ( abundant lymphoblasts, marrow infiltration, splenomegaly, and isolated lymphomas ( Fig. 3f-h; Supplementary Information, Fig. S3a-e (Fig. 4a) . Overall, expression levels of all predicted miR-19 targets were decreased more than those for other genes (P < 2 × 10 −4
; Kolmogorov-Smirnov test) (Fig. 4b) . Among these were also potentially interesting candidates such as the Pten tumour suppressor. However, there was no significant enrichment of miR-19 targets among genes showing more pronounced (1.5 or 2 s.d.) decreases in expression (P > 0.46 at 2 s.d.; P > 0.077 at 1.5 s.d.; Fisher's exact test) ( Fig. 4c ; Supplementary Information, Table S5 ). Thus, expression analysis and target prediction readily confirm global effects of miR-19 and may lead to promising candidates, but they do not provide strong enough filters to identify the most relevant miR-19 targets.
Genetic screens can pinpoint functionally relevant miRNA target genes We wondered whether an unbiased genetic screen might be an alternative method for the functional identification of miR-19 targets involved in lymphocyte survival. Specifically, we reasoned that a short hairpin RNA (shRNA) screen 25, 26 for genes whose knockdown phenocopied miR-19 in lymphocytes should also identify the genes responsible for miR-19 action. We conducted extensive control experiments with increasing dilutions of miR-19 and also a shRNA against Bim (Bcl2L11), a known target of the 17-92 cluster 9, 10 (Supplementary Information, Fig. S4a-d) . We then devised a screening protocol involving transduction of FL5-12 cells with pools of about 1,000 shRNAs, and two cycles of IL-3 depletion or continued passage in complete medium (Fig. 5a ). We used custom half-hairpin arrays to measure changes in the abundance of shRNAs in treated (without IL-3) versus untreated (including IL-3) samples at two time points (t 1 and t 2 equal one or two cycles of IL-3 depletion, respectively) 27 . Unsupervised clustering showed good reproducibility between biological replicates (A-C; correlation coefficient r = 0.60 ± 0.17; mean ± s.d.), and revealed a progressive shift in shRNAs across subsequent cycles of IL-3 depletion (Fig. 5b) . Statistical tools helped us to identify biologically significant signals. A significance analysis of microarrays (SAM) identified changes in individual shRNAs ( Fig. 5c ; see Supplementary Information, Table S6 , for the full analysis). A gene set analysis (GSA) defined groups of shRNAs targeting the same genes. The GSA identified 14 genes, each targeted by at least two and up to five different shRNAs, and the top 'hit' was the α subunit of AMPactivated kinase (Prkaa1) targeted by five independent shRNAs ( Fig. 5d ; see Supplementary Information, Table S7 , for the full analysis).
We individually validated candidate genes in the same experimental system. We included nearly all genes identified from the GSA, and also tested protein-coding genes from the SAM above an arbitrary threshold (at least 1.65-fold increase; P < 0.05). In total, we retested more than 70 genes and typically three shRNAs against each (all genes included in the validation are highlighted in Supplementary Information, Tables S6  and S7 ). Ultimately, shRNAs against eight genes positively validated and produced a survival benefit in FL5-12 cells depleted of IL-3 (in triplicate experiments P (vector/not shown) > 0.2; P (for all shRNAs) < 0.05; t-test) (Fig. 5e ). The positive validation rate was about 10%, and this may reflect the lower stringency of the SAM, which included genes targeted by just one shRNA. Strikingly, in the human genome five of the eight validated 'hits' harboured binding sequences for miR-19. Besides the pro-apoptotic Bim 9 , these were the tumour suppressor gene Pten 9 and the genes encoding the α subunit of AMP-activated kinase (Prkaa1), the ε isoform of PP2A (Ppp2r5e), and dedicator of cytokinesis-5 (Dock5). In addition, we validated three other genes that did not contain miR-19-binding sites in their 3´ untranslated regions (UTRs), namely those encoding the FoxO transcription factors FoxO1 and FoxO3, and Bnip3, a regulator of Rheb/ mTOR and Bcl2-binding protein. Taken together, the results of this unbiased genetic screen for shRNAs that behave like miR-19 showed a highly significant enrichment for genes containing miR-19-binding sites (P < 7.2 × 10 −7 by Fisher's exact test; Fig. 6a ). Unlike the human DOCK5 gene, the mouse gene is not a miR-19 target, and calculation of the enrichment statistics for the murine genome confirmed similarly high significance levels (P < 3.2 × 10 −5 by Fisher's exact test; Fig. 6b ). The prediction of miR-19 sites is based on Targetscan and did not take into account potential non-classical miRNA-binding sites, for example those in the coding sequence. However, some of the eight genes also harbour potential coding-sequence sites; these are shown in Supplementary Information, Table S13 . Thus, our unbiased, large-scale shRNA screen identified five human and four murine genes whose knockdown phenocopied miR-19 action in lymphocyte survival and that harboured miR-19-binding sites in their 3´ UTRs.
miR-19 acts through a coordinate effect on several negative regulators of phosphatidylinositol-3-OH kinase signals
We now wished to test whether miR-19 actually regulates the expression of these genes. Reporter assays confirmed direct 3´ UTR inhibition mediated by the predicted binding sites for these genes (n = 3) ( Information, Fig. S5a , b) and also in FL5-12 cells (Fig. 7b) , in which we consistently observed up to twofold decreases (n = 3; P (vector vs. miR-19) < 0.05 for all four genes; t-test) (Supplementary Information, Table S8 ). Conversely, an antagomir against miR-19 caused an increase in mRNA levels in vitro (n = 3; P (vector versus anti-19) < 0.05 for all four genes) ( Fig. 7c ; Supplementary Information, Table S8 ), and both miR-19 and the antagomir had measurable effects on protein levels. For example, miR-19 produced a clear decrease in PPP2R5E, PRKAA1 and BIM, and resulted in overall activation of phosphatidylinositol-3-OH kinase (PI(3)K) signalling, as indicated by increased phosphorylation of Akt and the ribosomal S6 protein (Fig. 7d, e) , whereas we did not detect an effect of miR-19 on PTEN protein, its mRNA was clearly decreased, and the antagomir produced increases in all miR-19 target proteins including PTEN (Fig. 7c, d ).
As expected, neither miR-19 nor the antagomir had an effect on Bnip3, which does not contain a 3´ UTR site for miR-19 (Fig. 7d) . The larger effects of the antagomir in comparison with miR-19 expression may indicate that these genes are tonically suppressed by the endogenous miR-19 in proliferating cells. Hence, we confirm that the expression of Bim, Pten 9 , Prkaa1 and Ppp2r5e is regulated by miR-19 in lymphocytes.
Next, we wondered about the contribution of these multiple target genes to miR-19 action. The pro-apoptotic BIM protein opposes Bcl2 and is an important regulator of lymphocyte survival 28 . To measure whether miR-19 had effects independent of Bim, we conducted complementation studies with FL5-12 cells engineered to stably express Bcl2 (FL5-12/Bcl2 cells). As expected, the Bim shRNA conferred no additional benefit, whereas miR-19 and the shRNAs against Pten and Pp2r5e showed continued enrichment Supplementary Information, Fig. S6 ). Uncropped images of blots are shown in Supplementary Information, Fig. S8 .
in the presence of Bcl2 (Fig. 8a) . Conversely, an antagomir against miR-19 produced anti-proliferative effects, and FL5-12/Bcl2 cells expressing the antagomir were lost on continued passage (Fig. 8b) . Similarly, miR-19 maintained its protective effect in the presence of metformin-activated AMP kinase or enforced expression of Pten or Pp2r5e ( Supplementary  Information, Fig. S5c ). This indicates that multiple target genes contribute to miR-19 action in vitro. In vivo we found that individual knockdown of some targets was sufficient to accelerate leukaemogenesis. This was most striking for Pten (n = 4, vector n = 10; P < 0.001) and Bim (n = 6; P < 0.001), whereas shRNA against Prkaa1 produced a modest effect (n = 5; P = 0.3), and knockdown of Pp2r5e alone was unable to drive leukaemogenesis (n = 4) (Fig. 8c) . Overall our data identify multiple miR-19 targets that together act on PI(3)K-related signals and affect lymphocyte survival in vitro and leukaemogenesis in vivo (Fig. 8d) .
DISCuSSION
Our results provide new insights into the oncogenic activity of the miR-17-92 cluster in T-cell leukaemia. miR-19, expressed at levels seen in human tumours, enhances lymphocyte survival and can promote c-Mycinduced B-cell lymphomagenesis 13, 14 . Moreover, miR-19 is sufficient to cooperate with Notch1 in T-ALL in vivo. Given the conservation of the entire 17-92 cluster, it is likely that these miRNAs perform important functions in other tissues or biological processes, or that the co-expression of these miRNAs produces additional effects 11 . The interaction of Notch1 and miR-19 is a relevant pathogenic mechanism in T-ALL. This is most strikingly demonstrated by the coexistence in the same leukaemic clone of two translocations activating the NOTCH1 gene (t(9;14) (q34;q11)) and targeting the 17-92 cluster (t(13;14)(q32;q11)), respectively. It is likely that other mechanisms, for example transcriptional activation by c-Myc and Notch1, are more common causes of the increased miR-19 expression that we observed in T-ALL specimens. Clearly, miR-19 is an important oncogene within the 17-92 cluster and contributes to the molecular pathogenesis of lymphoma and T-cell leukaemia.
We have identified a pattern of gene regulation by miR-19. Using an unbiased shRNA screening approach we have found eight genes whose knockdown recapitulates miR-19 effects in vitro. Intriguingly, in the human genome, five of these 'hits' harbour miR-19-binding sites and are regulated by miR-19. It is likely that these genes are among the key effectors of miR-19 action in lymphocyte survival and that the regulation of multiple genes contributes to the overall activity of miR-19. These include Bim, encoding a pro-apoptotic Bcl2 protein and target of the 17-92 cluster 12 , and also Prkaa1 (encoding AMP-activated kinase), the tumour suppressor phosphatases Pp2a (subunit Ppp2r5e) and Pten 8 (Fig. 8d) . A candidate gene approach combining the analysis of predicted miR-19 targets and expression data has also pointed to Pten in a mouse lymphoma model 13, 14 . Other miRNAs encoded in the 17-92 cluster are predicted to target some of the same genes, suggesting a potential mechanism for the functional cooperation between these clustered miRNAs 8 . These results suggest that miR-19 coordinates a PI(3)K-pathway-related program of cell survival in lymphocytes that contributes to leukaemogenesis.
Our results validate a new functional genomics approach for identifying miRNA target genes. A genetic screen provides an unbiased tool with which to pinpoint miRNA target genes that may be responsible for a specific phenotype, such as lymphocyte survival. Some limitations should be noted, for example that shRNAs and miRNAs act through somewhat distinct mechanisms 3, 29 . Further, our screen is based on shRNAs that target single genes whose individual knockdown is sufficient to recapitulate the effect of miR-19. It is likely that these genes are among the key effectors of miR-19. However, we may overlook weaker targets whose effect is apparent only in the context of additional expression changes. shRNA and screens are an evolving technology, and limitations of detection and shRNA validation may account for the overall low (10%) validation rate. Despite these limitations, our data indicate that phenotype-based genetic screens provide an unbiased tool with which to pinpoint functionally important miRNA targets. In this manner, genetic screens can complement computational 4,30 and genomic/proteomic 5, 7 methods in deciphering the complexity of gene regulation by miRNAs.
MeTHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/ Note: Supplementary Information is available on the Nature Cell Biology website.
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Cell culture, viability, proliferation assays and vector constructs. FL5-12 murine lymphocytes, cell cycle, apoptosis studies and viral transductions were as described 17, 31 . All vectors are based on murine stem cell virus, and include the miRNA expression vector encoding miR17, miR18a, miR19b-1 (miR- 19 Supplementary Information, Fig. S6 ) and vector constructs ( Supplementary  Information, Fig. S7a, b , and Supplementary Information, Table S10) ). The miRNA pool contained 48 miRNAs (all 17-92 and additional control miRNAs; the complete list is available from the authors on request). Expression of 17-92 miRs in FL5-12 cells is shown in Supplementary Information, Fig. S7c . The antagomirs MZIP19a-PA-1, MZIP19b-PA-1 and scrambled control (MZIP000-PA-1) were from System Biosciences ( Supplementary Information, Fig. S7d) .
Generation of mice. The mouse T-ALL and EµMyc lymphoma models have been reported 23, 32 . Data were analysed in Kaplan-Meier format with the log-rank (Mantel-Cox) test for statistical significance. The p53 LOH PCR and surface marker analysis were as described 32 .
Western blot analysis. Immunoblots were performed from whole-cell lysates as described 32 . Antibodies were against Prkaa1 (2532, 1:1,000 dilution; Cell Signaling), Bim/Bcl2L11 (AAP-330, 1:1,000; Assay Designs), FoxO1 (94545, 1:1,000; Cell Signaling), FoxO3a (9467, 1:1,000; Cell Signaling), phospho-FoxO3a (94665, 1:1,000; Cell Signaling), Ppp2r5e (NB 100-845; Novus), Pten (9559, 1:1,000; Cell Signaling), tubulin (B-5-1-2, 1:5,000; Sigma), actin (AC-15, 1:5,000; Sigma), Bnip3 (3769, 1:1,000; Cell Signaling), phosphorylated S6 (2215, 1:1,000; Cell Signaling) and phosphorylated Akt (4058, 1:1,000; Cell Signaling). The Dock5 antibody was a gift from Alan Hall (Memorial Sloan-Kettering Cancer Center).
Real-time quantitative PCR.
Total RNA and miRNA-enriched RNA were extracted with the Allprep DNA/RNA/Protein (Qiagen) and miRNeasy Mini (Qiagen) kits. Pathological diagnosis was by expert haematopathologists at Weill Cornell University. cDNA synthesis and qRT-PCR and analysis by the ∆∆C t method as described 31 . Taqman Gene Expression Assays: Bcl2l11 (Mm00437796_ m1), Dock5 (Mm00555757_m1), FoxO1 (Mm00490672_m1), FoxO3 (Mm01185722_m1), Ppp2r5e (Mm00803759_m1), Prkaa1 (Mm01296695_m1), Pten (Mm01212532_m1), mouse GAPD (GAPDH; 4352932; Applied Biosystems) and miR-19b (000396, Applied Biosystems) expression was normalized to RNU6B (001093; Applied Biosystems); primer sequences for miRNA detection are available from the authors on request.
Luciferase assays. The Dock5, Ppp2r5e, Prkaa1 and Bim 3´-UTR fragments (Supplementary Information, Table S11) were generated by PCR and cloned into the psi-CHECK-2 vector (Promega). The assays were performed as described 9 . The binding-site mutants were generated by site-directed mutagenesis ( Supplementary Information, Table S12 ).
Karyotype and fluorescence in situ hybridization (FISH) analysis. Metaphase chromosome preparations made from primary lymphoblasts from patients were subjected to karyotype analysis by following standard procedures. Genomic clones RP11-97P7 and RP11-980D6 located at 13q32 were from Invitrogen. DNA was labelled by nick-translation with spectrum orange dUTP fluorochrome (Vysis). A spectrum-green-labelled RB1 probe was used as control for chromosome 13q hybridization. FISH was performed by standard methods on cells used for cytogenetic analysis. Hybridization signals were scored on at least 20 metaphase spreads on 4,6-diamidino-2-phenylindole-stained slides, with the Cytovision Imaging system attached to a Nikon Eclipse 600 microscope (Applied Imaging).
Amplification of aberrant NOTCH1 transcripts by 5´ rapid amplification of cDNA ends (RACE). mRNA was extracted from primary lymphoblasts from patients by using the Nucleotrap mRNA extraction kit from Clontech, and 5´ RACE was performed with the SMART RACE kit (Clontech) by using a oligonucleotide primer complementary to the sequence of exon 29 of the NOTCH1 gene (5´-TCGTCCATGAGGGCACCGTCTGAAG-3´).
Pooled shRNA library screen. The pooled shRNA screen and half-hairpin array detection has been described; the library has been cloned from the original PSM2 constructs into the MRP vector and it contains about 14,000 distinct shRNAs, pooled into 1,000 shRNAs per pool 26, 27, 31 . FL5-12 cells were transduced at low multiplicity of infection in triplicates and each was subjected to two cycles of IL-3 depletion and rescue (t 1 and t 2 ). Samples were collected after viability had recovered for DNA isolation, PCR amplification of integrated shRNAs or the library as a reference; these were labelled and hybridized. Data generated (Nimblescan software) from image scans (Axon 4000BScanner) were imported into R version 2.4 for processing and analysis. Each Nimblegen 12-plex custom array consists of 12,033 half-hairpin probes (sequences are available from the authors on request). Most were represented by shRNAs in the library, and the remainder were used for background estimation. Negative control spots showed lower intensities than the experimental probes on each array ( Supplementary Information, Fig. S7e) . Signal values below background were replaced with the background estimate to dampen large ratios resulting from low signal. The two channels for each array were then normalized with loess normalization, and log ratios of the normalized intensity were used in further analyses.
Data analysis for pooled shRNA screens. The analyses were performed with the Bioconductor linear models for microarray (limma) 33 , SAM 34 and GSA 35 libraries in R. Correlations between biological replicates were calculated for each time point, and principal component analyses were performed to determine the magnitude of experimental effects and biological replicates. Biological replicates did not constitute a major source of variation in the experiment. The mean correlation for biological replicates was 0.60 ± 0.17 s.d., and probably reflected random variations as populations drifted in culture. Biologically significant signals were identified with the SAM software to select probes reflecting differences in relative abundance of shRNAs. We used the unpaired two-class algorithm, which assumes independent samples of each feature across the conditions. Q values are calculated empirically and used for identifying significant features. Overall, a gene was scored as being a potential candidate if its shRNA probe was found to fulfil these criteria: at least 1.65-fold change, P < 0.05, and current gene bank annotation with a corresponding protein. Further testing was performed with GSA to identify candidates based on data from multiple hairpins targeting the same gene; because each gene is targeted by two to four hairpins, their fold changes are summed. This statistic was compared with the same statistic from exhaustive permutation to arrive at empirical P values for each gene. All gene sets showing a positive fold change in the GSA were included in validations (except olfactory receptor481). These cutoffs are relatively arbitrary and were chosen as a conservative criterion to minimize false positives.
Computational analysis of shRNA off-target effects. We performed several computational analyses to investigate whether the results of the screen might be attributable to off-target effects. We considered two hypotheses: first, that shRNAs over-represented in the screen have a sequence similarity to miR-19 itself and hence mimic miR-19 activity through sites in 3´ UTRs; and second, that results of the screen are explainable by microRNA-like off-target effects on a few key genes. We ranked all shRNAs by ungapped sequence similarity of, on the one hand, the shRNA 'seed' (positions 2-8) to the miR-19 seed region and, on the other hand, the shRNA to the full-length miR-19a and miR-19b sequences. No shRNAs in the library had the same heptamer seed region as miR-19; among the shRNAs whose seed region matched the miR-19 heptamer seed at six positions (12 shRNAs with hexamer seeds matching positions 3-8, two shRNAs with hexamer seeds matching positions 2-7), none were in the top 100 shRNAs over-represented in the screen. The maximal sequence similarity between shRNAs in the library and the full-length miR-19a/b sequences was a 13-base ungapped match; 23 shRNAs had this degree of similarity to miR-19a and/or miR-19b, but none of them occurred in the top 100 over-represented shRNAs from the screen. Moreover, we found poor Spearman rank correlation (|ρ| < 0.01) between the ranking of shRNAs by over-representation in the screen and these similarity comparisons to miR-19. Next, we considered whether shRNAs that were highly ranked in the screen were more likely to have predicted off-target effects on Pten, Prkaa1, Bcl2l11, Ppp2r5e, Dock5, Foxo1, Foxo3 And Bnip3, compared with the full library. If this were true, over-representation of an shRNA in the screen might be explainable through off-target silencing of these key genes. To predict potential microRNA-like off-target effects of shRNAs, we scanned 3´ UTRs in the entire mouse genome for matches to heptamer seed sequences (positions 2-8, no conservation filter) of shRNAs in the library. A gene with a heptamer seed match for a given shRNA was considered to be a predicted off-target for this shRNA. We nature cell biology then tested whether, for any of the eight genes, the set of shRNAs that were predicted to 'off-target' the gene were enriched in the top K over-represented shRNAs from the screen, in comparison with the full shRNA library. We used values of K ranging from 2 to 250, and we did not observe statistical significance by a Fisher's exact test for any value of K (P > 0.05 in all cases for each gene). These controls indicate that the shRNAs are not similar to miR-19 itself and that the screen result could not be explained by off-target effects of top-ranked shRNAs on key genes. We computed the enrichment statistic with respect to the number of unique targets of the roughly 12,000 shRNAs in the library and the subset of these targets that were also predicted miR-19 targets; we used Fisher's exact test to account for the small number of 'hits' . This analysis was performed for both the human and the murine genome. Target predictions were as defined in Targetscan 5.1.
Expression array analysis.
RNA isolation, quality control, cRNA synthesis, labelling hybridization and scanning were performed in accordance with standard protocols and the manufacturer's instructions (Affymetrix) and analysed with Partek Genomic Suite 6.4. For statistical analysis, we centred the data with the mean log 2 (expression change) of genes and normalized them to have unit variance in log 2 (expression change) across all genes. This normalization results in a modified Z-transformation of the data (Z-score). These data have been deposited in NCBI's Gene Expression Omnibus 24 under GEO accession number GSE20097 (http:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20097).
Kolmogorov-Smirnov (KS) statistic.
To compare the expression changes for miR-19 targets with those for all genes, we compared their distributions of log(expression change) values by using a one-sided KS statistic, which assesses whether the distribution of expression changes for one set is significantly shifted downwards (downregulated) compared with the distribution for the other set. The KS statistic computes the maximum difference in value of the empirical cumulative distribution functions:
where (9;14) ; e, Higher resolution of double colour FISH pointing to the existence of a T-ALL oncogene localizing to the 17~92 cluster (same as shown in Figure 2 ). Analysis using a RB1 probe (green) in 13q14 and genomic clones RP11-97P7 and RP11-980D6 overlapping the 17~92 locus in 13q32 (red). Probe RP11-97P7 shows a split signal with retention of half of the clone in chromosome 13 and the other half mapping to the derivative chromosome 14. Probe RP11-980D6 shows small retention of signal in chromosome 13 and with most of the clone mapping to the derivative chromosome 14. der (14) der (14) der ( T0 T1 T2  T0 T1 T2  T0 T1 T2  T0 T1 T2  T0 T1 T2   5 
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